Literature DB >> 1351503

Murine AIDS superantigen reactivity of the T cells bearing V beta 5 T cell antigen receptor.

O Kanagawa1, B A Nussrallah, M E Wiebenga, K M Murphy, H C Morse, F R Carbone.   

Abstract

A B cell line, B6-1710, that expresses the defective virus known to induce murine AIDS stimulates a large fraction of nonprimed splenic T cells. Analysis of the T cell population responding to the B6-1710 for TCR V beta-chain usage revealed that, in addition to the previously reported V beta 5-chain-positive T cells, T cells bearing V beta 11 and V beta 12 are also specifically enriched. We have established V beta 5+ T cell lines, clones, and hybridomas expressing identical TCR with different CD4/CD8 phenotypes and demonstrated that T cell reactivity to B6-1710 is, although not absolute, dependent on the presence of CD4 molecules. Further analysis of T cell hybridomas with known J beta-chain usage revealed that D beta- and J beta-chain usage do not play crucial roles in T cell reactivity to B6-1710 B cells. However, T cell hybridomas derived from TCR-V beta gene transgenic mice were found to be heterogeneous for their reactivity to B6-1710, suggesting that the V alpha-chains associating with the transgenic V beta-chain determine T cell responsiveness to B6-1710. These data clearly demonstrate that T cell reactivity to a murine AIDS virus expressing B cell line resembles that previously reported for Mls-like superantigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351503

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Endogenous Mtv-encoded superantigens are not required for development of murine AIDS.

Authors:  T C McCarty; S K Chattopadhyay; M T Scherer; T N Fredrickson; J W Hartley; H C Morse
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.

Authors:  B C Cho; J D Shaughnessy; D A Largaespada; H G Bedigian; A M Buchberg; N A Jenkins; N G Copeland
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 3.  Revenge of the microbes. Superantigens of the T and B cell lineage.

Authors:  L Goodglick; J Braun
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 4.  Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice.

Authors:  H C Morse; N Giese; R Morawetz; Y Tang; R Gazzinelli; W K Kim; S Chattopadhyay; J W Hartley
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.

Authors:  K A Green; K M Crassi; J D Laman; A Schoneveld; R R Strawbridge; T M Foy; R J Noelle; W R Green
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Evidence that the murine AIDS defective virus does not encode a superantigen.

Authors:  L Doyon; C Simard; R P Sékaly; P Jolicoeur
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Negative segregation of Mtv loci in H-2E+ mice selected for high antibody response.

Authors:  T Roger; S Boudaly; M Seman
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 8.  Superantigenic characteristics of mouse mammary tumor viruses play a critical role in susceptibility to infection in mice.

Authors:  C E Pucillo; L D Palmer; R J Hodes
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

9.  T cell receptor-major histocompatibility complex class II interaction is required for the T cell response to bacterial superantigens.

Authors:  N Labrecque; J Thibodeau; W Mourad; R P Sékaly
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  Major histocompatibility complex-specific recognition of Mls-1 is mediated by multiple elements of the T cell receptor.

Authors:  D L Woodland; H P Smith; S Surman; P Le; R Wen; M A Blackman
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.